Literature DB >> 7062951

Decreased hepatic uroporphyrinogen decarboxylase activity in porphyria cutanea tarda.

B F Felsher, N M Carpio, D W Engleking, A T Nunn.   

Abstract

To test whether reduced hepatic uroporphyrinogen decarboxylase activity is a specific and intrinsic defect in porphyria cutanea tarda, we measured enzymatic activity in the livers of 17 patients with porphyria cutanea tarda, 12 "normal" control patients without liver disease, and 41 patients with other forms of porphyria, alcoholic liver disease, hemochromatosis, or chronic hepatitis. Enzyme activity in all the patients with porphyria cutanea tarda was lower than in the patients without this disease, except for one patient with alcohol-induced fatty liver. Reduction of hepatic iron stores by phlebotomy did not alter the enzymatic activity in porphyria cutanea tarda. We conclude that reduced hepatic uroporphyrinogen decarboxylase activity is a specific and intrinsic hepatic defect in porphyria cutanea tarda, but modulation of uroporphyrinogen synthesis by extrinsic factors is required for the full biochemical expression of the disease.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7062951     DOI: 10.1056/NEJM198204013061302

Source DB:  PubMed          Journal:  N Engl J Med        ISSN: 0028-4793            Impact factor:   91.245


  10 in total

1.  The genetic basis of porphyria cutanea tarda.

Authors:  R Enriquez de Salamanca; A Olmos; M L Peña; L Berges; J Perpiñá
Journal:  Arch Dermatol Res       Date:  1985       Impact factor: 3.017

2.  Porphyria cutanea tarda and hepatitis C virus infection in a patient with acute liver failure.

Authors:  R M Jasmer; M S Larson; K N Weilbaecher
Journal:  West J Med       Date:  1994-11

3.  Different types of porphyria cutanea tarda.

Authors:  M Doss; H Sauer; F Sixel-Dietrich; R von Tiepermann
Journal:  Arch Dermatol Res       Date:  1984       Impact factor: 3.017

Review 4.  [Hepatic porphyrias and alcohol].

Authors:  M O Doss; A Kühnel; U Gross; I Sieg
Journal:  Med Klin (Munich)       Date:  1999-06-15

5.  Autoantibodies to human cytosol: a marker of sporadic porphyria cutanea tarda.

Authors:  Y Ma; A L Fracanzani; M Sampietro; M Mattioli; P Cheeseman; R Williams; G Mieli-Vergani; D Vergani; S Fargion
Journal:  Clin Exp Immunol       Date:  2001-10       Impact factor: 4.330

6.  Enzymatic and immunological studies of uroporphyrinogen decarboxylase in familial porphyria cutanea tarda and hepatoerythropoietic porphyria.

Authors:  H de Verneuil; C Beaumont; J C Deybach; Y Nordmann; Z Sfar; R Kastally
Journal:  Am J Hum Genet       Date:  1984-05       Impact factor: 11.025

7.  Vinyl chloride-induced hepatic coproporphyrinuria with transition to chronic hepatic porphyria.

Authors:  M Doss; C E Lange; G Veltman
Journal:  Klin Wochenschr       Date:  1984-02-15

8.  Effects of polychlorinated biphenyl compounds, 2,3,7,8-tetrachlorodibenzo-p-dioxin, phenobarbital and iron on hepatic uroporphyrinogen decarboxylase. Implications for the pathogenesis of porphyria.

Authors:  H De Verneuil; S Sassa; A Kappas
Journal:  Biochem J       Date:  1983-07-15       Impact factor: 3.857

9.  An unhappy triad: hemochromatosis, porphyria cutanea tarda and hepatocellular carcinoma-a case report.

Authors:  Martina-T Mogl; Andreas Pascher; Sabine-J Presser; Michael Schwabe; Peter Neuhaus; Natascha-C Nuessler
Journal:  World J Gastroenterol       Date:  2007-04-07       Impact factor: 5.742

10.  A porphomethene inhibitor of uroporphyrinogen decarboxylase causes porphyria cutanea tarda.

Authors:  John D Phillips; Hector A Bergonia; Christopher A Reilly; Michael R Franklin; James P Kushner
Journal:  Proc Natl Acad Sci U S A       Date:  2007-03-09       Impact factor: 11.205

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.